A prospective study of adjuvant CMF in males with node positive breast cancer: 20-Year follow-up

Janice M. Walshe, Arlene W. Berman, Ujala Vatas, Seth M. Steinberg, William F. Anderson, Marc E. Lippman, Sandra M. Swain

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Purpose: To determine the long-term overall survival of male patients with stage II node positive breast cancer treated with adjuvant chemotherapy. Patients and methods: Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute. Following mastectomy, patients were treated with 12 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy. Results: Median patient age was 61 years (38-74 years). Twenty-one patients (68%) had 1-3 positive axillary lymph nodes while ten patients (32%) had four or more positive nodes. Estrogen receptor status was positive in 22 (71%), negative in 1 (3%), and unknown in 8 (26%) tumors. Progesterone receptor status was positive in 18 (58%), negative in 3 (10%), and unknown in 10 (32%) tumors. Median potential follow-up for all patients is 22.5 years with a median survival of 16.3 years. Twenty-one of 31 patients have died; one from a treatment-related complication, nine patients from recurrent breast cancer, five from other cancers, one from non-cancer related causes, and five from unknown causes. Ten patients remain alive at a median of 19.2 years. The overall survival probability at 10 years is 64.5% (95% CI: 46.9-78.9%), at 15 years is 51.6% (95% CI: 34.8-68%), and at 20 years is 42.4% (95% CI: 25.8-60.8%). Conclusion: To our knowledge, 20-year prospective data with adjuvant chemotherapy in male breast cancer has never been reported. Adjuvant chemotherapy may benefit male breast cancer patients with positive nodes.

Original languageEnglish (US)
Pages (from-to)177-183
Number of pages7
JournalBreast cancer research and treatment
Volume103
Issue number2
DOIs
StatePublished - Jun 1 2007

    Fingerprint

Keywords

  • Adjuvant chemotherapy
  • CMF chemotherapy
  • Male breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Walshe, J. M., Berman, A. W., Vatas, U., Steinberg, S. M., Anderson, W. F., Lippman, M. E., & Swain, S. M. (2007). A prospective study of adjuvant CMF in males with node positive breast cancer: 20-Year follow-up. Breast cancer research and treatment, 103(2), 177-183. https://doi.org/10.1007/s10549-006-9363-0